NSB 7.69% 3.6¢ neuroscientific biopharmaceuticals ltd

Ann: Investor Webinar Presentation, page-10

  1. 417 Posts.
    lightbulb Created with Sketch. 115
    yes there have been delays in the start of phase 1 trials but there has been a mountain of pre clinical work done, they haven’t just been sitting on their hands

    and Alexandra was asked in the webinar about fast track approval and whilst she wasn’t able to elaborate on the details she said it has been discussed.

    if this if obtained it will be MASSIVE!
 
watchlist Created with Sketch. Add NSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.